180 related articles for article (PubMed ID: 3009551)
1. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D.
Balsan S; Garabédian M; Larchet M; Gorski AM; Cournot G; Tau C; Bourdeau A; Silve C; Ricour C
J Clin Invest; 1986 May; 77(5):1661-7. PubMed ID: 3009551
[TBL] [Abstract][Full Text] [Related]
2. Hereditary resistance to 1,25-dihydroxyvitamin D: clinical and radiological improvement during high-dose oral calcium therapy.
Sakati N; Woodhouse NJ; Niles N; Harfi H; de Grange DA; Marx S
Horm Res; 1986; 24(4):280-7. PubMed ID: 3023230
[TBL] [Abstract][Full Text] [Related]
3. Rickets and alopecia with resistance to 1,25-dihydroxyvitamin D: two different clinical courses with two different cellular defects.
Balsan S; Garabedian M; Liberman UA; Eil C; Bourdeau A; Guillozo H; Grimberg R; Le Deunff MJ; Lieberherr M; Guimbaud P; Broyer M; Marx SJ
J Clin Endocrinol Metab; 1983 Oct; 57(4):803-11. PubMed ID: 6309886
[TBL] [Abstract][Full Text] [Related]
4. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
Harrell RM; Lyles KW; Harrelson JM; Friedman NE; Drezner MK
J Clin Invest; 1985 Jun; 75(6):1858-68. PubMed ID: 3839245
[TBL] [Abstract][Full Text] [Related]
5. Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse.
Marie PJ; Travers R; Glorieux FH
Calcif Tissue Int; 1982 Mar; 34(2):158-64. PubMed ID: 6282410
[TBL] [Abstract][Full Text] [Related]
6. Long-term intracaval calcium infusion therapy in end-organ resistance to 1,25-dihydroxyvitamin D.
Weisman Y; Bab I; Gazit D; Spirer Z; Jaffe M; Hochberg Z
Am J Med; 1987 Nov; 83(5):984-90. PubMed ID: 2823606
[TBL] [Abstract][Full Text] [Related]
7. The effects of 1,25-dihydroxyvitamin D3 and dexamethasone on rat osteoblast-like primary cell cultures: receptor occupancy and functional expression patterns for three different bioresponses.
Chen TL; Hauschka PV; Cabrales S; Feldman D
Endocrinology; 1986 Jan; 118(1):250-9. PubMed ID: 3000737
[TBL] [Abstract][Full Text] [Related]
8. A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D.
Marx SJ; Spiegel AM; Brown EM; Gardner DG; Downs RW; Attie M; Hamstra AJ; DeLuca HF
J Clin Endocrinol Metab; 1978 Dec; 47(6):1303-10. PubMed ID: 233695
[TBL] [Abstract][Full Text] [Related]
9. Response to parathyroid hormone and 1,25-dihydroxyvitamin D3 of bone-derived cells isolated from normal children and children with abnormalities in skeletal development.
Silve C; Grosse B; Tau C; Garabedian M; Fritsch J; Delmas PD; Cournot-Witmer G; Balsan S
J Clin Endocrinol Metab; 1986 Mar; 62(3):583-90. PubMed ID: 3003145
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D-dependent rickets type II. Defective induction of 25-hydroxyvitamin D3-24-hydroxylase by 1,25-dihydroxyvitamin D3 in cultured skin fibroblasts.
Gamblin GT; Liberman UA; Eil C; Downs RW; DeGrange DA; Marx SJ
J Clin Invest; 1985 Mar; 75(3):954-60. PubMed ID: 3872316
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
Drezner MK; Lyles KW; Haussler MR; Harrelson JM
J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
[TBL] [Abstract][Full Text] [Related]
12. Absent intestinal response to calciferols in hereditary resistance to 1,25-dihydroxyvitamin D: documentation and effective therapy with high dose intravenous calcium infusions.
Bliziotes M; Yergey AL; Nanes MS; Muenzer J; Begley MG; Vieira NE; Kher KK; Brandi ML; Marx SJ
J Clin Endocrinol Metab; 1988 Feb; 66(2):294-300. PubMed ID: 2828407
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the relation between alopecia and resistance to 1,25-dihydroxyvitamin D.
Marx SJ; Bliziotes MM; Nanes M
Clin Endocrinol (Oxf); 1986 Oct; 25(4):373-81. PubMed ID: 3040300
[TBL] [Abstract][Full Text] [Related]
14. 1,25-dihydroxyvitamin D resistance, rickets, and alopecia: analysis of receptors and bioresponse in cultured fibroblasts from patients and parents.
Chen TL; Hirst MA; Cone CM; Hochberg Z; Tietze HU; Feldman D
J Clin Endocrinol Metab; 1984 Sep; 59(3):383-8. PubMed ID: 6086691
[TBL] [Abstract][Full Text] [Related]
15. A new point mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor in a kindred with hereditary 1,25-dihydroxyvitamin D-resistant rickets.
Yagi H; Ozono K; Miyake H; Nagashima K; Kuroume T; Pike JW
J Clin Endocrinol Metab; 1993 Feb; 76(2):509-12. PubMed ID: 8381803
[TBL] [Abstract][Full Text] [Related]
16. Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3.
Gundberg CM; Cole DE; Lian JB; Reade TM; Gallop PM
J Clin Endocrinol Metab; 1983 May; 56(5):1063-7. PubMed ID: 6601111
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D metabolism in pregnant rabbits: differences between the maternal and fetal response to administration of large amounts of vitamin D3.
Kubota M; Ohno J; Shiina Y; Suda T
Endocrinology; 1982 Jun; 110(6):1950-6. PubMed ID: 6280980
[TBL] [Abstract][Full Text] [Related]
18. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII).
al-Aqeel A; Ozand P; Sobki S; Sewairi W; Marx S
Clin Endocrinol (Oxf); 1993 Aug; 39(2):229-37. PubMed ID: 8396512
[TBL] [Abstract][Full Text] [Related]
19. 1 alpha-hydroxyvitamin D3 treatment of three patients with 1,25-dihydroxyvitamin D-receptor-defect rickets and alopecia.
Takeda E; Kuroda Y; Saijo T; Naito E; Kobashi H; Yokota I; Miyao M
Pediatrics; 1987 Jul; 80(1):97-101. PubMed ID: 3037475
[TBL] [Abstract][Full Text] [Related]
20. Normal 24-hydroxylation of vitamin D metabolites in patients with vitamin D-dependency rickets type I. Structural implications for the vitamin D hydroxylases.
Mandla S; Jones G; Tenenhouse HS
J Clin Endocrinol Metab; 1992 Apr; 74(4):814-20. PubMed ID: 1548347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
